Financial Results, Dividends, and Upcoming Earnings - Research Reports on Continental, Sherwin-Williams, Nucor, Polaris and Boston Scientific

NEW YORK, October 28, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Continental Resources, Inc. (NYSE: CLR), The Sherwin-Williams Company (NYSE: SHW), Nucor Corporation (NYSE: NUE), Polaris Industries Inc. (NYSE: PII) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7484-100free.

--
Continental Resources, Inc. Research Reports
On October 9, 2014, Continental Resources, Inc. (Continental) announced that it intends to report its Q3 2014 earnings on Wednesday, November 5, 2014 following the close of trading on the New York Stock Exchange. The Company informed that it also plans to host a conference call to discuss the results on November 6, 2014 at 12:00 p.m. ET (11:00 a.m. CT). Continental added that the call and replay of the same will be available at its website. The Company informed that prior to the call it intends to publish a Q3 2014 supplement presentation at its website on November 6, 2014. The full research reports on Continental are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/CLR/report.pdf

--
The Sherwin-Williams Company Research Reports
On October 23, 2014, The Sherwin-Williams Company (Sherwin-Williams) reported that its Board of Directors has announced a regular quarterly dividend of $0.55 per common share. According to the Company, the said dividend is payable on December 5, 2014, to shareholders of record as on November 14, 2014. The full research reports on Sherwin-Williams are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/SHW/report.pdf

--
Nucor Corporation Research Reports
On October 23, 2014, Nucor Corporation (Nucor) announced its Q3 FY 2014 (period ended October 4, 2014) financial results. Net sales stood at $5.7 billion, up 15.4% YoY. Net earnings were reported at $245.4 million or $0.76 per diluted share, compared to $147.6 million or $0.46 per diluted share in Q3 FY 2013. For the 9M FY 2014, Nucor reported net earnings of $503.5 million, or $1.57 per diluted share, compared with $317.5 million, or $0.99 per diluted share, in 9M FY 2013. In the same release, the Company added that in September, 2014, Nucor's Board of Directors has declared a cash dividend of $0.37 per share, payable on November 10, 2014 to stockholders of record as on September 30, 2014. The full research reports on Nucor are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/NUE/report.pdf

--
Polaris Industries Inc. Research Reports
On October 22, 2014, Polaris Industries Inc. (Polaris) announced its Q3 2014 earnings results. The Company reported total sales of $1.3 billion, up 18.1% YoY. Net income from continuing operations stood at $140.8 million or $2.06 per diluted share, versus $116.9 million or $1.64 per diluted share in Q3 2013. Scott Wine, Polaris' Chairman and CEO said, "Our strong third quarter results reflect the continued execution of our long-term strategy and broad strength across our industry-leading portfolio. Amid heightened competition we garnered strong retail sales in all categories, even as we introduced more than 20 new off-road vehicles and motorcycles and over 300 new complementary accessories for our consumers." For 2014, Polaris expects sales to grow in the range of 17% to 18% YoY, whereas the Company has increased its guidance for earnings from continuing operations to a range of $6.55 to $6.65 per diluted share, up 21% to 23% over 2013. The full research reports on Polaris are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/PII/report.pdf

--
Boston Scientific Corporation Research Reports
On October 22, 2014, Boston Scientific Corporation (Boston Scientific) announced its Q3 2014 financial results. The Company reported net sales of $1.846 billion, up 6.4 % YoY, which also exceeded the Company's guidance range of $1.790 billion to $1.840 billion. Net income stood at $43 million or $0.03 per diluted shares, versus net loss of 5 million in Q3 2013. Mike Mahoney, President and CEO, Boston Scientific said, "We achieved excellent third quarter results, growing most of our divisions faster than the market while delivering strong, double-digit EPS growth. We are particularly pleased with our global performance in Cardiovascular and Rhythm Management. Our momentum continues, and we are excited about the opportunities we have ahead to strengthen our global execution and bring more unique innovation to patients." For Q4 2014, the Company estimates sales to be in a range of $1.875 billion to $1.925 billion, while earnings are anticipated to range $0.09 to $0.11 per share. For full-year 2014, Boston Scientific revised its revenue guidance to a range of $7.370 billion to $7.420 billion from its prior guidance range of $7.325 billion to $7.425 billion. 2014 earnings are expected to be in a range of $0.22 to $0.24 per share, compared to prior guidance of $0.28 to $0.32. The full research reports on Boston Scientific are available to download free of charge at:

http://www.analystsreview.com/Oct-28-2014/BSX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED